2018
DOI: 10.1084/jem.20171193
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes

Abstract: Du et al. demonstrate that PKCδ modulates BACE1 expression and amyloidogenic amyloid precursor protein processing. Inhibition of PKCδ markedly reduces BACE1 expression, β-amyloid levels, and amyloid plaque formation and also rescues cognitive deficits in Alzheimer disease mouse models.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
44
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 54 publications
(45 citation statements)
references
References 82 publications
(113 reference statements)
0
44
1
Order By: Relevance
“…One unexpected finding of our study was the transient reduction of APP despite persistent PCKβ knockdown. Past studies of PKC modulators in APP transgenic mice have generally tested just a single time point of shorter duration than examined here, and none have suggested a mechanism based on APP stability (49,50,(53)(54)(55)(56). We found that transgenic APP levels were significantly reduced following 1 month of PKCβ knockdown, but this effect lost potency as the animals aged.…”
Section: Discussionmentioning
confidence: 54%
See 1 more Smart Citation
“…One unexpected finding of our study was the transient reduction of APP despite persistent PCKβ knockdown. Past studies of PKC modulators in APP transgenic mice have generally tested just a single time point of shorter duration than examined here, and none have suggested a mechanism based on APP stability (49,50,(53)(54)(55)(56). We found that transgenic APP levels were significantly reduced following 1 month of PKCβ knockdown, but this effect lost potency as the animals aged.…”
Section: Discussionmentioning
confidence: 54%
“…Whereas trans-genic overexpression of PKCε diminished Aβ via degradation, PKCδ knockdown in mice lowered Aβ via BACE1. Reduction of PKCδ in primary neurons from APP transgenic mice decreased BACE1 expression, β-site APP cleavage and Aβ production, while chronic treatment with rotterlin to inhibit PKCδ in vivo reiterated these effects and delayed plaque onset (50). These two experiments hint that PKC isoforms may act in opposition to control Aβ levels, yet few isoforms have been selectively manipulated in vivo to isolate their effect.…”
Section: Discussionmentioning
confidence: 97%
“…Several studies uncovered crucial functions of PRKCD in AD: a) A stimulated protein kinase C delta type (PRKCD) to phosphorylate myristoylated alanine-rich C-kinase substrate (MARCKS) in microglia 19 and phosphorylation of MARCKS was observed in microglia within plaques 20 ; and b) inhibition of PRKCD reverse A levels 21 . Spleen tyrosine kinase (SYK) has been shown to play a role in AD pathological lesions, and SYK was therefore considered as a potential drug target for AD 22 .…”
Section: Discovery Of Disease-associated Microglia Specific Molecularmentioning
confidence: 99%
“…Since PKCs-related pathways have been involved in the control of memory and learning processes, their role in cognitive disorders were investigated [43,44,45,46]. These cognitive disorders include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Vascular Dementia, and Huntington Disease (HD).…”
Section: Protein Kinase Cs In Brain and Neurological Diseasesmentioning
confidence: 99%